Details for Patent: 7,982,043
✉ Email this page to a colleague
Which drugs does patent 7,982,043 protect, and when does it expire?
Patent 7,982,043 protects NERLYNX and is included in one NDA.
This patent has one patent family member in one country.
Summary for Patent: 7,982,043
| Title: | Protein tyrosine kinase enzyme inhibitors |
| Abstract: | This invention provides compounds of formula 1, having the structure ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are described within the specification. |
| Inventor(s): | Wissner; Allan (Ardsley, NY), Rabindran; Sridhar Krishna (Chestnut Ridge, NY), Tsou; Hwei-Ru (New City, NY) |
| Assignee: | Wyeth LLC (Madison, NJ) |
| Application Number: | 12/136,357 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,982,043 |
|
Patent Claim Types: see list of patent claims | Use; |
More… ↓ |
Drugs Protected by US Patent 7,982,043
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,982,043 | ⤷ Subscribe | EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY | ⤷ Subscribe | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,982,043 | ⤷ Subscribe | USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING | ⤷ Subscribe | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,982,043 | ⤷ Subscribe | EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,982,043
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005028443 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
